Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

被引：87

作者：

Villeger, Romain ^{[1
]}

Lopes, Amelie ^{[1
,2
]}

Carrier, Guillaume ^{[1
,3
]}

Veziant, Julie ^{[1
,4
,5
]}

Billard, Elisabeth ^{[1
]}

Barnich, Nicolas ^{[1
]}

Gagniere, Johan ^{[1
,4
,5
]}

Vazeille, Emilie ^{[1
,5
,6
]}

Bonnet, Mathilde ^{[1
]}

机构：

[1] Univ Clermont Auvergne, CRNH Auvergne, INSERM, INRA,USC 2018,UMR 1071,M2iSH, F-63000 Clermont Ferrand, France

[2] Sanofi R&D, Biol Res, F-94400 Vitry Sur Seine, France

[3] Univ Montpellier, ICM, Surg Oncol Dept, F-34298 Montpellier, France

[4] Univ Clermont Auvergne, CHU Clermont Ferrand, INSERM, Serv Chirurg Digest, F-63003 Clermont Ferrand, France

[5] Univ Clermont Auvergne, CHU Clermont Ferrand, INSERM, 3iHP, F-63003 Clermont Ferrand, France

[6] Univ Clermont Auvergne, CHU Clermont Ferrand, INSERM, Serv Hepatogastroenterol, F-63003 Clermont Ferrand, France

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2019年 / 20卷 / 18期

关键词：

intestinal microbiota; chemotherapy; probiotics; cancer; radiotherapy; anticancer treatment; surgery; microbiome; adjuvant therapies; INTERNATIONAL SCIENTIFIC ASSOCIATION; COLORECTAL-CANCER; GUT MICROBIOTA; ANASTOMOTIC LEAKAGE; PHYSICAL-ACTIVITY; PSEUDOMONAS-AERUGINOSA; CONSENSUS STATEMENT; CYTOSTATIC ACTIVITY; FECAL MICROBIOTA; DOUBLE-BLIND;

D O I：

10.3390/ijms20184584

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recently, preclinical and clinical studies targeting several types of cancer strongly supported the key role of the gut microbiota in the modulation of host response to anti-tumoral therapies such as chemotherapy, immunotherapy, radiotherapy and even surgery. Intestinal microbiome has been shown to participate in the resistance to a wide range of anticancer treatments by direct interaction with the treatment or by indirectly stimulating host response through immunomodulation. Interestingly, these effects were described on colorectal cancer but also in other types of malignancies. In addition to their role in therapy efficacy, gut microbiota could also impact side effects induced by anticancer treatments. In the first part of this review, we summarized the role of the gut microbiome on the efficacy and side effects of various anticancer treatments and underlying mechanisms. In the second part, we described the new microbiota-targeting strategies, such as probiotics and prebiotics, antibiotics, fecal microbiota transplantation and physical activity, which could be effective adjuvant therapies developed in order to improve anticancer therapeutic efficiency.

引用

页数：25

共 174 条

[1] Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors [J].